1-甲基-1H-苯并咪唑-4-羧酸 | 672957-92-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-甲基-1H-苯并咪唑-4-羧酸
• 英文名称: 1-Methyl-4-benzimidazolecarboxylic Acid
• 英文别名: 1-methylbenzimidazole-4-carboxylic acid
• CAS: 672957-92-5
• 化学式: C₉H₈N₂O₂
• 分子量: 176.17
• InChiKey: KANGLPGGTDOWJO-UHFFFAOYSA-N

物化性质

• 密度：
  1.35

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20200102303A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.

  化合物的结构式（I）和结构式（II），含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法，例如与疼痛、精神障碍、神经障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症）、癌症和眼部疾病相关的方法。 其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。
• Heterocyclic Derivative and Pharmaceutical Drug
  申请人：Otsu Hironori

  公开号：US20140221339A1

  公开（公告）日：2014-08-07

  The present invention provides a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. For example, the present invention provides a heterocyclic derivative of the general formula [1] or its tautomer, or a pharmaceutically acceptable salt thereof: wherein R 1 and R 2 are the same or different aromatic rings, etc., and ring A is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mPGES-1 inhibiting activity and is useful as an agent for the treatment or prevention of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease.

  本发明提供了一种新型的杂环衍生物或其药学上可接受的盐。例如，本发明提供了一种通式[1]或其互变异构体的杂环衍生物，或其药学上可接受的盐：其中R1和R2是相同或不同的芳香环等，环A是杂环。本发明的化合物或其药学上可接受的盐具有强效的mPGES-1抑制活性，并可用作治疗或预防疾病的药物，例如类风湿性关节炎、骨关节炎、颞下颌关节紊乱、腰痛、子宫内膜异位症、痛经、过度活动的膀胱、恶性肿瘤或神经退行性疾病的药物。
• HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL DRUG
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP2746265A1

  公开（公告）日：2014-06-25

  The present invention provides a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. For example, the present invention provides a heterocyclic derivative of the general formula [1] or its tautomer, or a pharmaceutically acceptable salt thereof: wherein R1 and R2 are same or diferent aromatic ring, etc., and ring A is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mPGES-1 inhibiting activity and is useful as an agent for the treatment or prevension of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease.

  本发明提供了一种新型杂环衍生物或其药学上可接受的盐。例如，本发明提供了通式[1]的杂环衍生物或其同系物，或其药学上可接受的盐： 其中 R1 和 R2 是相同或不同的芳香环等，环 A 是杂环。 本发明的化合物或其药学上可接受的盐具有强效的 mPGES-1 抑制活性，可用作治疗或预防疾病的药物，如类风湿性关节炎、骨关节炎、颞下颌关节紊乱、腰背痛、子宫内膜异位症、痛经、膀胱过度活动症、恶性肿瘤或神经退行性疾病。
• Muscarinic M1 receptor positive allosteric modulators
  申请人：SUVEN LIFE SCIENCES LIMITED

  公开号：US11040026B2

  公开（公告）日：2021-06-22

  The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).

  本发明涉及作为毒蕈碱 M1 受体正异位调节剂（M1 PAMs）的式（I）化合物或其同位素形式、立体异构体、同系物或药学上可接受的盐。本发明描述了式 (I) 化合物的制备、药物组合物和用途。
• HETEROCYCLIC DERIVATIVE AS MICROSOMAL PROSTAGLANDIN E SYNTHASE (mPGEs) INHIBITOR
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP2746265B1

  公开（公告）日：2015-11-18